

Michael A Nauck

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5147965/publications.pdf>

Version: 2024-02-01

301
papers

46,910
citations

3668

92
h-index

2072

211
g-index

339
all docs

339
docs citations

339
times ranked

25319
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus report: Definition and interpretation of remission in type 2 diabetes. <i>Diabetic Medicine</i> , 2022, 39, e14669.	1.2	15
2	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1-9.	1.8	32
3	Acute effects of linagliptin on intact and total glucagon-like peptide-1 and gastric inhibitory polypeptide levels in insulin-dependent type 2 diabetes patients with and without moderate renal impairment. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 806-815.	2.2	0
4	Comment: Type 1 diabetes and oral health: Findings from the Epidemiology of Diabetes Interventions and Complications (EDIC) study. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108146.	1.2	0
5	Understanding the restrictions in the prescription and use of potentially beneficial diabetes medications associated with low socio-economic status. <i>Lancet Regional Health - Europe</i> , The, 2022, 14, 100318.	3.0	3
6	Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. <i>Circulation</i> , 2022, 145, 575-585.	1.6	88
7	Insulin clearance and incretin hormones following oral and α -isoglycemic intravenous glucose in type 2 diabetes patients under different antidiabetic treatments. <i>Scientific Reports</i> , 2022, 12, 2510.	1.6	3
8	Measurement of Gastric Emptying Using a ^{13}C -octanoic Acid Breath Test with Wagner-Nelson Analysis and Scintigraphy in Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2022, 130, 751-757.	0.6	7
9	Comparison of Insulin-Treated Patients with Ambiguous Diabetes Type with Definite Type 1 and Type 2 Diabetes Mellitus Subjects: A Clinical Perspective. <i>Diabetes and Metabolism Journal</i> , 2022, , .	1.8	0
10	Report from the CVOT Summit 2021: new cardiovascular, renal, and glyceic outcomes. <i>Cardiovascular Diabetology</i> , 2022, 21, 50.	2.7	8
11	SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease. <i>Trends in Endocrinology and Metabolism</i> , 2022, 33, 424-442.	3.1	23
12	Efficacy and Safety of Tirzepatide versus Semaglutide Once Weekly as Add-on Therapy to Metformin in People with Type 2 Diabetes (SURPASS-2). <i>Diabetologie Und Stoffwechsel</i> , 2022, , .	0.0	0
13	Therapy of Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2022, 130, S80-S112.	0.6	5
14	Patients with Type 1 Diabetes Treated with Insulin Pumps Need Widely Heterogeneous Basal Rate Profiles Ranging from Negligible to Pronounced Diurnal Variability. <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 1262-1272.	1.3	8
15	GLP-1 receptor agonists in the treatment of type 2 diabetes " state-of-the-art. <i>Molecular Metabolism</i> , 2021, 46, 101102.	3.0	518
16	COVID-19 and diabetes mellitus: from pathophysiology to clinical management. <i>Nature Reviews Endocrinology</i> , 2021, 17, 11-30.	4.3	653
17	Day-to-Day Variations in Fasting Plasma Glucose Do Not Influence Gastric Emptying in Subjects With Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 479-488.	4.3	10
18	Twenty-Four Hour Fasting (Basal Rate) Tests to Achieve Custom-Tailored, Hour-by-Hour Basal Insulin Infusion Rates in Patients With Type 1 Diabetes Using Insulin Pumps (CSII). <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 360-370.	1.3	12

#	ARTICLE	IF	CITATIONS
19	Owning a Dog as a Determinant of Physical Activity and Metabolic Control in Patients With Type 1 and Type 2 Diabetes Mellitus. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2021, 129, 379-384.	0.6	4
20	Reply to: Autonomic dyshomeostasis in patients with diabetes mellitus during COVID-19. <i>Nature Reviews Endocrinology</i> , 2021, 17, 189-190.	4.3	2
21	Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6. <i>Frontiers in Endocrinology</i> , 2021, 12, 645566.	1.5	42
22	Voices: Insulin and beyond. <i>Cell Metabolism</i> , 2021, 33, 692-699.	7.2	3
23	Long COVID “metabolic risk factors and novel therapeutic management. <i>Nature Reviews Endocrinology</i> , 2021, 17, 379-380.	4.3	38
24	Another milestone in the evolution of GLP-1-based diabetes therapies. <i>Nature Medicine</i> , 2021, 27, 952-953.	15.2	3
25	Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2344-2353.		8
26	Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 525-544.	5.5	121
27	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. <i>Diabetes Care</i> , 2021, 44, 2438-2444.	4.3	152
28	Consensus report: definition and interpretation of remission in type 2 diabetes. <i>Diabetologia</i> , 2021, 64, 2359-2366.	2.9	39
29	The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 5-29.	2.2	139
30	Incretin-based therapies in 2021 – Current status and perspectives for the future. <i>Metabolism: Clinical and Experimental</i> , 2021, 122, 154843.	1.5	19
31	No evidence of tachyphylaxis for insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) in subjects with type 2 diabetes, their first-degree relatives, or in healthy subjects. <i>Peptides</i> , 2020, 125, 170176.	1.2	3
32	Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. <i>Peptides</i> , 2020, 125, 170183.	1.2	61
33	The relationship between plasma GIP and GLP-1 levels in individuals with normal and impaired glucose tolerance. <i>Acta Diabetologica</i> , 2020, 57, 583-587.	1.2	5
34	The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationship. <i>Metabolism: Clinical and Experimental</i> , 2020, 103, 154031.	1.5	12
35	Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 599-611.	2.2	10
36	Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 699-704.	2.2	75

#	ARTICLE	IF	CITATIONS
37	Reduced COVID-19 Mortality With Sitagliptin Treatment? Weighing the Dissemination of Potentially Lifesaving Findings Against the Assurance of High Scientific Standards. <i>Diabetes Care</i> , 2020, 43, 2906-2909.	4.3	30
38	Prediction of Individual Basal Rate Profiles From Patient Characteristics in Type 1 Diabetes on Insulin Pump Therapy. <i>Journal of Diabetes Science and Technology</i> , 2020, 15, 193229682097269.	1.3	3
39	Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis. <i>Diabetes Care</i> , 2020, 43, 2303-2312.	4.3	54
40	Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001706.	1.2	31
41	Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. <i>Diabetes Care</i> , 2020, 43, 1546-1552.	4.3	92
42	The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (<sc>GLP</sc>-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective <sc>long-acting GLP</sc>-1 receptor agonists. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1886-1891.	2.2	53
43	Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. <i>Diabetes Care</i> 2019;42:1912-1920. <i>Diabetes Care</i> , 2020, 43, e30-e31.	4.3	1
44	Risk of hypoglycaemia associated with professional, recreational, and traffic-related activities in patients with type 2 diabetes: a cross-sectional study by questionnaire. <i>Acta Diabetologica</i> , 2020, 57, 965-972.	1.2	0
45	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1128-1141.	1.2	53
46	GLP-1 receptor agonists in type 1 diabetes: a MAGIC bullet?. <i>Lancet Diabetes and Endocrinology</i> , the, 2020, 8, 262-264.	5.5	13
47	SGLT-2 Inhibition and the Endocrine Pancreatic Alpha Cell: Direct or Indirect Mechanisms of Inhibition?. <i>Endocrinology</i> , 2020, 161, .	1.4	1
48	Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the <sc>LEADER</sc> and <sc>SUSTAIN</sc> 6 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2193-2198.	2.2	11
49	Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 2137-2145.	4.3	21
50	Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 938-946.	2.2	126
51	Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the <sc>DEVOTE</sc>, <sc>LEADER</sc> and <sc>SUSTAIN</sc> 6 cardiovascular outcomes trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1537-1547.	2.2	54
52	Islet Amyloid in Patients With Diabetes Due to Exocrine Pancreatic Disorders, Type 2 Diabetes, and Nondiabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2595-2605.	1.8	13
53	Longitudinal Changes in Fasting and Glucose-Stimulated GLP-1 and GIP in Healthy Older Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 6201-6206.	1.8	15
54	Clinical Predictors of the Need for Further Treatment Escalation in Patients with Type 2 Diabetes on Basal Insulin Therapy - A Retrospective Observational Study. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 663-671.	0.6	6

#	ARTICLE	IF	CITATIONS
55	Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. <i>Diabetes Care</i> , 2019, 42, 1912-1920.	4.3	35
56	Effects of the Glucagon-Like Peptide-1 (GLP-1) Analogues Semaglutide and Liraglutide on Renal Outcomes – A Pooled Analysis of the SUSTAIN 6 and LEADER Trials. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	4
57	EGFR Loss with Glucagon-Like Peptide-1 (GLP-1) Analogue Treatment: Data from SUSTAIN 6 and LEADER. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	3
58	Effects of Semaglutide and Liraglutide on Urinary Albumin-to-Creatinine Ratio (UACR) – A Pooled Analysis of SUSTAIN 6 and LEADER. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	4
59	Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2450-2458.	2.2	8
60	Occurrence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events. <i>JAMA Cardiology</i> , 2019, 4, 1214.	3.0	39
61	Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS. <i>Cardiovascular Diabetology</i> , 2019, 18, 116.	2.7	14
62	Glucagon-like peptide 1 (GLP-1). <i>Molecular Metabolism</i> , 2019, 30, 72-130.	3.0	850
63	Importance of localization of insulinomas: a systematic analysis. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2019, 26, 383-392.	1.4	15
64	Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. <i>Lancet, The</i> , 2019, 394, 39-50.	6.3	315
65	Pioneering oral peptide therapy for patients with type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 500-502.	5.5	4
66	Effect of portal glucose sensing on incretin hormone secretion in a canine model. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 317, E244-E249.	1.8	7
67	GIP and GLP-1: Stepsiblings Rather Than Monozygotic Twins Within the Incretin Family. <i>Diabetes</i> , 2019, 68, 897-900.	0.3	39
68	Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1745-1751.	2.2	22
69	Therapy of Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, S73-S92.	0.6	38
70	Health-related quality of life in people with type 2 diabetes participating in the LEADER trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 525-532.	2.2	21
71	Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 499-508.	2.2	71
72	MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?. <i>European Journal of Endocrinology</i> , 2019, 181, R211-R234.	1.9	156

#	ARTICLE	IF	CITATIONS
73	58-OR: The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to a Selective Long-Acting GLP-1 Receptor Agonist. <i>Diabetes</i> , 2019, 68, 58-OR.	0.3	2
74	993-P: A 12-Week, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Three Dose-Escalation Algorithms of Tirzepatide, a Novel Dual GIP and GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes. <i>Diabetes</i> , 2019, 68, 993-P.	0.3	1
75	Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials. <i>Diabetes and Metabolism Journal</i> , 2019, 43, 410.	1.8	21
76	55-OR: Oral Semaglutide vs. Liraglutide and Placebo in T2D: PIONEER 4. <i>Diabetes</i> , 2019, 68, .	0.3	0
77	Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns. <i>Trends in Endocrinology and Metabolism</i> , 2018, 29, 238-248.	3.1	55
78	Incretin hormones: Their role in health and disease. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 5-21.	2.2	451
79	Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial). <i>American Journal of Cardiology</i> , 2018, 121, 1467-1470.	0.7	25
80	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2018, 392, 1519-1529.	6.3	1,179
81	Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. <i>Lancet, The</i> , 2018, 392, 2180-2193.	6.3	528
82	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. <i>Circulation</i> , 2018, 138, 2884-2894.	1.6	82
83	Liraglutide and Glycaemic Outcomes in the LEADER Trial. <i>Diabetes Therapy</i> , 2018, 9, 2383-2392.	1.2	23
84	Risk of hypoglycaemia in people aged ≥65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus. <i>International Journal of Clinical Practice</i> , 2018, 72, e13240.	0.8	5
85	Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease. <i>Circulation</i> , 2018, 137, 2179-2183.	1.6	80
86	Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial. <i>Diabetes and Vascular Disease Research</i> , 2018, 15, 465-468.	0.9	22
87	Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. <i>Circulation</i> , 2018, 138, 1605-1607.	1.6	25
88	Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. <i>Diabetes Care</i> , 2018, 41, 1663-1671.	4.3	51
89	Incretin Hormone Release Does Not Involve Hepatic Portal Vein Glucose Sensors. <i>Diabetes</i> , 2018, 67, 1961-P.	0.3	0
90	Liraglutide Effects in Insulin-Treated Patients in LEADER. <i>Diabetes</i> , 2018, 67, 438-P.	0.3	2

#	ARTICLE	IF	CITATIONS
91	Basal rate tests (24-hour fasts) performed in type 1 diabetic subjects with either absolute fasting or snacks containing negligible carbohydrate amounts result in similar glucose profiles: <sc>A</sc> randomized controlled prospective trial. Diabetes, Obesity and Metabolism, 2017, 19, 783-790.	2.2	0
92	Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide. Diabetes Care, 2017, 40, 647-654.	4.3	20
93	Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardiovascular outcome trials. Diabetes, Obesity and Metabolism, 2017, 19, 1327-1328.	2.2	17
94	Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial. Diabetes Care, 2017, 40, 966-972.	4.3	63
95	A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite. American Journal of Physiology - Endocrinology and Metabolism, 2017, 313, E284-E291.	1.8	13
96	A case series of verrucae vulgares mimicking hyperkeratosis in individuals with diabetic foot ulcers. Diabetic Medicine, 2017, 34, 1165-1168.	1.2	5
97	Sitagliptin plus basal insulin: simplifying in-hospital diabetes treatment?. Lancet Diabetes and Endocrinology, the, 2017, 5, 83-85.	5.5	10
98	Liraglutide and Renal Outcomes in Type 2 Diabetes: Results of the LEADER Trial. Canadian Journal of Diabetes, 2017, 41, S5.	0.4	1
99	Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation, 2017, 136, 849-870.	1.6	415
100	Break point instead of ACE: acarbose, post-load glycaemic excursions, and cardiovascular events. Lancet Diabetes and Endocrinology, the, 2017, 5, 843-845.	5.5	2
101	Defects in Î±-Cell Function in Patients With Diabetes Due to Chronic Pancreatitis Compared With Patients With Type 2 Diabetes and Healthy Individuals. Diabetes Care, 2017, 40, 1314-1322.	4.3	21
102	Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice, 2017, 131, 49-60.	1.1	26
103	Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide 1 receptor agonists: A systematic analysis of published clinical trials. Diabetes, Obesity and Metabolism, 2017, 19, 336-347.	2.2	194
104	Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide 1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 200-207.	2.2	28
105	A meta-analysis comparing clinical effects of short- or long-acting <sc>GLP</sc> 1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes, Obesity and Metabolism, 2017, 19, 216-227.	2.2	123
106	A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes. Diabetes Care, 2016, 39, 231-241.	4.3	149
107	Feedback suppression of meal-induced glucagon-like peptide 1 (<sc>GLP</sc> 1) secretion mediated through elevations in intact <sc>GLP</sc> 1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment. Diabetes, Obesity and Metabolism, 2016, 18, 1100-1109.	2.2	17
108	Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist. Diabetes, 2016, 65, 2440-2447.	0.3	43

#	ARTICLE	IF	CITATIONS
109	Fasting C-peptide and Related Parameters Characterizing Insulin Secretory Capacity for Correctly Classifying Diabetes Type and for Predicting Insulin Requirement in Patients with Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2016, 124, 148-156.	0.6	10
110	Improvement in glycated haemoglobin evaluated by baseline body mass index: a meta-analysis of the liraglutide phase III clinical trial programme. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 707-710.	2.2	10
111	Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 1253-1262.	2.2	13
112	GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 963-964.	5.5	17
113	Incretin mimetics and insulin "closing the gap to normoglycaemia. <i>Nature Reviews Endocrinology</i> , 2016, 12, 689-690.	4.3	2
114	Impact of diabetes duration on achieved reductions in glycated haemoglobin, fasting plasma glucose and body weight with liraglutide treatment for up to 28 weeks: a meta-analysis of seven phase III trials. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 721-724.	2.2	9
115	Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial. <i>Diabetes Care</i> , 2016, 39, 1501-1509.	4.3	126
116	Linagliptin and pioglitazone combination therapy versus monotherapy with linagliptin or pioglitazone: A randomised, double-blind, parallel-group, multinational clinical trial. <i>Diabetes and Vascular Disease Research</i> , 2016, 13, 286-298.	0.9	5
117	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 311-322.	13.9	5,070
118	Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52-week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. <i>Diabetologia</i> , 2016, 59, 266-274.	2.9	85
119	Novel approaches to treating type 2 diabetes. <i>Diabetologia</i> , 2016, 59, 227-228.	2.9	3
120	Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 203-216.	2.2	322
121	The insulinotropic effect of pulsatile compared with continuous intravenous delivery of GLP-1. <i>Diabetologia</i> , 2016, 59, 966-969.	2.9	1
122	The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 525-536.	5.5	310
123	Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 849-858.	2.2	108
124	Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 868-877.	2.2	20
125	GIP increases adipose tissue expression and blood levels of MCP-1 in humans and links high energy diets to inflammation: a randomised trial. <i>Diabetologia</i> , 2015, 58, 1759-1768.	2.9	73
126	Incretin-based therapies: where will we be 50 years from now?. <i>Diabetologia</i> , 2015, 58, 1745-1750.	2.9	39

#	ARTICLE	IF	CITATIONS
127	Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without) Tj ETQq1 1 0.784314 rgBT /Overlook and Metabolism, 2015, 17, 1056-1064.	2.2	89
128	Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 2015, 58, 429-442.	2.9	598
129	<scp>LEADER</scp> 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the <scp>L</scp>iraglutide <scp>E</scp>ffect and <scp>A</scp>ction in <scp>D</scp>iabetes: <scp>E</scp>valuation of cardiovascular outcome <scp>R</scp>esults (<scp>LEADER</scp> trial: preliminary observations. Diabetes, Obesity and Metabolism. 2015, 17, 477-486.	2.2	18
130	Effect of Exogenous Intravenous Administrations of GLP-1 and/or GIP on Circulating Pro-Atrial Natriuretic Peptide in Subjects With Different Stages of Glucose Tolerance. Diabetes Care, 2015, 38, e7-e8.	4.3	8
131	Effects of glucose-dependent insulinotropic polypeptide on gastric emptying, glycaemia and insulinaemia during critical illness: a prospective, double blind, randomised, crossover study. Critical Care, 2015, 19, 20.	2.5	18
132	Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2015, 38, 140-149.	4.3	2,326
133	Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Design, Development and Therapy, 2014, 8, 1335.	2.0	279
134	Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia. Diabetes, 2014, 63, 785-790.	0.3	120
135	Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes. Diabetes Care, 2014, 37, 2763-2773.	4.3	211
136	LEADER 3â€”Lipase and Amylase Activity in Subjects With Type 2 Diabetes. Pancreas, 2014, 43, 1223-1231.	0.5	54
137	Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes and Endocrinology,the, 2014, 2, 289-297.	5.5	293
138	Pancreatitis and incretin-based drugs: clarity or confusion?. Lancet Diabetes and Endocrinology,the, 2014, 2, 92-93.	5.5	6
139	Effects of Sitagliptin and Metformin Treatment on Incretin Hormone and Insulin Secretory Responses to Oral and â€œsoglycemicâ€œIntravenous Glucose. Diabetes, 2014, 63, 663-674.	0.3	80
140	A randomised, controlled trial of self-monitoring of blood glucose in patients with type 2 diabetes receiving conventional insulin treatment. Diabetologia, 2014, 57, 868-877.	2.9	13
141	Polypharmacy in people with Type 1 and Type 2 diabetes is justified by current guidelinesâ€”a comprehensive assessment of drug prescriptions in patients needing inpatient treatment for diabetesâ€”associated problems. Diabetic Medicine, 2014, 31, 1078-1085.	1.2	43
142	Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management. Diabetes Care, 2014, 37, 2647-2659.	4.3	58
143	Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care, 2014, 37, 2149-2158.	4.3	236
144	Risk of pancreatitis in patients treated with incretin-based therapies. Diabetologia, 2014, 57, 1320-1324.	2.9	84

#	ARTICLE	IF	CITATIONS
145	Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 1111-1120.	2.2	93
146	Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. <i>Lancet</i> , 2013, 381, 117-124.	6.3	466
147	Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?. <i>Diabetologia</i> , 2013, 56, 1878-1883.	2.9	36
148	A Critical Analysis of the Clinical Use of Incretin-Based Therapies. <i>Diabetes Care</i> , 2013, 36, 2126-2132.	4.3	189
149	Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial. <i>American Heart Journal</i> , 2013, 166, 823-830.e5.	1.2	182
150	Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 1330-1339.	1.5	12
151	A1C Improvement with Liraglutide Evaluated by Baseline BMI. <i>Canadian Journal of Diabetes</i> , 2013, 37, S35-S36.	0.4	2
152	Do GLP-1-Based Therapies Increase Cancer Risk?. <i>Diabetes Care</i> , 2013, 36, S245-S252.	4.3	106
153	Diagnostic Accuracy of an Amended Insulin-Glucose Ratio for the Biochemical Diagnosis of Insulinomas. <i>Annals of Internal Medicine</i> , 2013, 158, 501.	2.0	1
154	Glucose-Dependent Insulinotropic Polypeptide Reduces Fat-Specific Expression and Activity of 11 β -Hydroxysteroid Dehydrogenase Type 1 and Inhibits Release of Free Fatty Acids. <i>Diabetes</i> , 2012, 61, 292-300.	0.3	47
155	Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 1986-1993.	4.3	58
156	Diagnostic Accuracy of an Amended Insulin-Glucose Ratio for the Biochemical Diagnosis of Insulinomas. <i>Annals of Internal Medicine</i> , 2012, 157, 767.	2.0	34
157	In vivo effect of glucose-dependent insulinotropic peptide (GIP) on the gene expression of calcitonin peptides in human subcutaneous adipose tissue. <i>Regulatory Peptides</i> , 2012, 179, 29-32.	1.9	2
158	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. <i>Diabetes Care</i> , 2012, 35, 1364-1379.	4.3	3,077
159	The design of the liraglutide clinical trial programme. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 4-12.	2.2	9
160	GLP-1 analogues and insulin: sound the wedding bells?. <i>Nature Reviews Endocrinology</i> , 2011, 7, 193-195.	4.3	24
161	Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications. <i>American Journal of Medicine</i> , 2011, 124, S3-S18.	0.6	255
162	Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?. <i>Diabetologia</i> , 2011, 54, 10-18.	2.9	402

#	ARTICLE	IF	CITATIONS
163	Glycaemic Rises after Waking Up in Response to an Alarm Clock in Type 1-diabetic Patients Analysed with Continuous Glucose Monitoring (GlucoDay® S). <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2011, 119, 56-58.	0.6	2
164	Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1695-1702.	1.8	125
165	Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin. <i>Diabetes Care</i> , 2011, 34, 2015-2022.	4.3	479
166	GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes. <i>Diabetes</i> , 2011, 60, 1270-1276.	0.3	141
167	Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 945-954.	1.8	60
168	Chronic Reduction of Fasting Glycemia With Insulin Glargine Improves First- and Second-Phase Insulin Secretion in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, 2048-2053.	4.3	41
169	Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans. <i>Diabetes</i> , 2011, 60, 1561-1565.	0.3	291
170	Metabolomic linkage reveals functional interaction between glucose-dependent insulinotropic polypeptide and ghrelin in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2011, 301, E608-E617.	1.8	8
171	Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β -Cell Function?. <i>Diabetes</i> , 2010, 59, 1117-1125.	0.3	189
172	Proinsulin levels in patients with pancreatic diabetes are associated with functional changes in insulin secretion rather than pancreatic β -cell area. <i>European Journal of Endocrinology</i> , 2010, 163, 551-558.	1.9	17
173	Genetic Determinants Predicting Efficacy of Glucose-Lowering Drugs?: A long way to go <i>Diabetes Care</i> , 2010, 33, 2123-2125.	4.3	5
174	Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin: A proof-of-concept study. <i>Diabetes Care</i> , 2010, 33, 1509-1515.	4.3	160
175	Impact of Exogenous Hyperglucagonemia on Postprandial Concentrations of Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4061-4065.	1.8	6
176	Confronting the Type 2 Diabetes Epidemic: the Emerging Role of Incretin-Based Therapies. <i>American Journal of Medicine</i> , 2010, 123, S2-S10.	0.6	32
177	Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure. <i>Journal of Diabetes Investigation</i> , 2010, 1, 24-36.	1.1	10
178	Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. <i>Lancet</i> , The, 2010, 375, 1447-1456.	6.3	534
179	Individualised incretin-based treatment for type 2 diabetes. <i>Lancet</i> , The, 2010, 376, 393-394.	6.3	14
180	Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: A double-blind placebo-controlled study. <i>Diabetes Care</i> , 2009, 32, 1237-1243.	4.3	107

#	ARTICLE	IF	CITATIONS
181	Incretin-Based Therapies. <i>Diabetes Care</i> , 2009, 32, S223-S231.	4.3	143
182	Adding Liraglutide to Oral Antidiabetic Drug Monotherapy: Efficacy and Weight Benefits. <i>Postgraduate Medicine</i> , 2009, 121, 5-15.	0.9	27
183	For Insulinomas, No Place to Hide. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4125-4126.	1.8	0
184	Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. <i>International Journal of Clinical Practice</i> , 2009, 63, 46-55.	0.8	187
185	Excess glycaemic excursions after an oral glucose tolerance test compared with a mixed meal challenge and self-measured home glucose profiles: is the OGTT a valid predictor of postprandial hyperglycaemia and vice versa?. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 213-222.	2.2	43
186	Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 1163-1172.	2.2	247
187	Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, 84-90.	4.3	991
188	Unraveling the Science of Incretin Biology. <i>European Journal of Internal Medicine</i> , 2009, 20, S303-S308.	1.0	43
189	Unraveling the Science of Incretin Biology. <i>American Journal of Medicine</i> , 2009, 122, S3-S10.	0.6	123
190	Preface. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009, 23, vii.	2.2	1
191	Self-Monitoring of Blood Glucose in Diabetes Mellitus. <i>Deutsches Arzteblatt International</i> , 2009, 106, 587-94.	0.6	6
192	Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. <i>Regulatory Peptides</i> , 2008, 151, 123-129.	1.9	208
193	Glucagon-like peptide-1 in type 2 diabetes: the I^2 and beyond. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 2-13.	2.2	18
194	Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?. <i>European Journal of Endocrinology</i> , 2008, 158, 773-784.	1.9	45
195	Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 606-607.	2.9	39
196	Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance. <i>Diabetes</i> , 2008, 57, 678-687.	0.3	307
197	Comparison of Pancreas-Transplanted Type 1 Diabetic Patients with Portal-Venous Versus Systemic-Venous Graft Drainage: Impact on Glucose Regulatory Hormones and the Growth Hormone/Insulin-Like Growth Factor-I Axis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 1758-1766.	1.8	32
198	Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 293, E849-E856.	1.8	65

#	ARTICLE	IF	CITATIONS
199	Preserved GLP-1 Effects in a Diabetic Patient with Cushing's Disease. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2007, 115, 146-150.	0.6	21
200	Hypoglycemia due to Paraneoplastic Secretion of Insulin-Like Growth Factor-I in a Patient with Metastasizing Large-Cell Carcinoma of the Lung. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1600-1605.	1.8	47
201	The Dipeptidyl Peptidase 4 Inhibitor Vildagliptin Does Not Accentuate Glibenclamide-Induced Hypoglycemia but Reduces Glucose-Induced Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide Secretion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4165-4171.	1.8	105
202	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. <i>Diabetes, Obesity and Metabolism</i> , 2007, 9, 194-205.	2.2	601
203	Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2007, 10, 070509203705001-???	2.2	23
204	A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. <i>Diabetologia</i> , 2007, 50, 259-267.	2.9	422
205	Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects. <i>Diabetologia</i> , 2007, 50, 806-813.	2.9	75
206	Response to comment on: Nauck MA, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. <i>Diabetologia</i> 50:259-267. <i>Diabetologia</i> , 2007, 50, 1563-1564.	2.9	13
207	The enteroinsular axis may mediate the diabetogenic effects of TCF7L2 polymorphisms. <i>Diabetologia</i> , 2007, 50, 2413-2416.	2.9	19
208	The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. <i>Lancet, The</i> , 2006, 368, 1696-1705.	6.3	3,287
209	Glucagon-Like Peptide 2 Stimulates Glucagon Secretion, Enhances Lipid Absorption, and Inhibits Gastric Acid Secretion in Humans. <i>Gastroenterology</i> , 2006, 130, 44-54.	0.6	218
210	Comment to: Patti ME, McMahon G, Mun EC et al. (2005) Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. <i>Diabetologia</i> 48:2236-2240. <i>Diabetologia</i> , 2006, 49, 607-608.	2.9	19
211	Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. <i>Diabetologia</i> , 2006, 49, 452-458.	2.9	244
212	Incretins and the development of type 2 diabetes. <i>Current Diabetes Reports</i> , 2006, 6, 194-201.	1.7	81
213	Five Weeks of Treatment with the GLP-1 Analogue Liraglutide Improves Glycaemic Control and Lowers Body weight in Subjects with Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2006, 114, 417-423.	0.6	128
214	Effects of Intravenous Glucagon-Like Peptide-1 on Gastric Emptying and Intragastric Distribution in Healthy Subjects: Relationships with Postprandial Glycemic and Insulinemic Responses. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 1916-1923.	1.8	172
215	The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 290, E1118-E1123.	1.8	90
216	To be or not to be--an incretin or enterogastrone?. <i>Gut</i> , 2006, 55, 148-150.	6.1	25

#	ARTICLE	IF	CITATIONS
217	Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls. <i>World Journal of Gastroenterology</i> , 2006, 12, 1874.	1.4	8
218	α-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients. <i>Diabetic Medicine</i> , 2005, 22, 470-476.	1.2	54
219	Glucagon-like peptide 1 (GLP-1) in biology and pathology. <i>Diabetes/Metabolism Research and Reviews</i> , 2005, 21, 91-117.	1.7	250
220	The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1. <i>Diabetologia</i> , 2005, 48, 608-611.	2.9	83
221	Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes. <i>Diabetologia</i> , 2005, 48, 1872-1881.	2.9	72
222	Erythromycin Antagonizes the Deceleration of Gastric Emptying by Glucagon-Like Peptide 1 and Unmasks Its Insulinotropic Effect in Healthy Subjects. <i>Diabetes</i> , 2005, 54, 2212-2218.	0.3	113
223	Plasma Glucose at Hospital Admission and Previous Metabolic Control Determine Myocardial Infarct Size and Survival in Patients With and Without Type 2 Diabetes: The Langendreer Myocardial Infarction and Blood Glucose in Diabetic Patients Assessment (LAMBDA). <i>Diabetes Care</i> , 2005, 28, 2551-2553.	4.3	73
224	Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. <i>Regulatory Peptides</i> , 2005, 128, 135-148.	1.9	160
225	Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5991-5997.	1.8	274
226	GIP as a Potential Therapeutic Agent?. <i>Hormone and Metabolic Research</i> , 2004, 36, 859-866.	0.7	42
227	Glucagon-like Peptide 1 (GLP-1) in the Treatment of Diabetes. <i>Hormone and Metabolic Research</i> , 2004, 36, 852-858.	0.7	61
228	Stimulation of Insulin Secretion by Intravenous Bolus Injection and Continuous Infusion of Gastric Inhibitory Polypeptide in Patients With Type 2 Diabetes and Healthy Control Subjects. <i>Diabetes</i> , 2004, 53, S220-S224.	0.3	73
229	Orlistat Augments Postprandial Increases in Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients: Response to Damci et al.. <i>Diabetes Care</i> , 2004, 27, 2770-2770.	4.3	2
230	Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in the Pathogenesis of Type 2 Diabetes. <i>Diabetes</i> , 2004, 53, S190-S196.	0.3	177
231	Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects. <i>Diabetes</i> , 2004, 53, 654-662.	0.3	277
232	Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?. <i>British Heart Journal</i> , 2004, 90, 9-12.	2.2	96
233	Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2004, 18, 587-606.	2.2	52
234	Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. <i>Regulatory Peptides</i> , 2004, 118, 89-97.	1.9	39

#	ARTICLE	IF	CITATIONS
235	Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. <i>Regulatory Peptides</i> , 2004, 122, 209-217.	1.9	105
236	Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. <i>Critical Care Medicine</i> , 2004, 32, 848-851.	0.4	87
237	Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 286, E621-E625.	1.8	117
238	Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. <i>Diabetologia</i> , 2003, 46, 798-801.	2.9	270
239	A 25-year follow-up study of glucose tolerance in first-degree relatives of type 2 diabetic patients: association of impaired or diabetic glucose tolerance with other components of the metabolic syndrome. <i>Acta Diabetologica</i> , 2003, 40, 163-172.	1.2	10
240	A hyperinsulinaemic, sequentially eu- and hypoglycaemic clamp test to characterize autonomous insulin secretion in patients with insulinoma. <i>European Journal of Clinical Investigation</i> , 2003, 27, 109-115.	1.7	15
241	Normalization of Glucose Concentrations and Deceleration of Gastric Emptying after Solid Meals during Intravenous Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2719-2725.	1.8	315
242	Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 1579-1585.	1.5	43
243	The reduction in hepatic insulin clearance after oral glucose is not mediated by Gastric inhibitory polypeptide (GIP). <i>Regulatory Peptides</i> , 2003, 113, 95-100.	1.9	18
244	Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide. <i>BioDrugs</i> , 2003, 17, 93-102.	2.2	52
245	Influence of an Antidiabetic Treatment with Sulfonylurea Drugs on Long-Term Survival after Acute Myocardial Infarction in Patients with Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2003, 111, 344-350.	0.6	19
246	Absence of a Memory Effect for the Insulinotropic Action of Glucagon-like Peptide 1 (GLP-1) in Healthy Volunteers. <i>Hormone and Metabolic Research</i> , 2003, 35, 551-556.	0.7	16
247	Postoperative oral glucose tolerance and stimulated insulin secretion: a predictor of endocrine graft function more than 10 years after pancreas-kidney transplantation. <i>Transplantation</i> , 2003, 76, 1427-1431.	0.5	18
248	Incretins and their analogues as new antidiabetic drugs. <i>Drug News and Perspectives</i> , 2003, 16, 413.	1.9	40
249	Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 1239-1246.	1.8	515
250	Combined Pancreas and Kidney Transplantation in a Lean Type 2 Diabetic Patient. Effects on Insulin Secretion and Sensitivity. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2002, 110, 420-424.	0.6	27
251	Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. <i>Lancet, The</i> , 2002, 360, 257.	6.3	1
252	Gastric Inhibitory Polypeptide: the neglected incretin revisited. <i>Regulatory Peptides</i> , 2002, 107, 1-13.	1.9	197

#	ARTICLE	IF	CITATIONS
253	Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. <i>European Journal of Pharmacology</i> , 2002, 440, 269-279.	1.7	115
254	Reduced Insulinotropic Effect of Gastric Inhibitory Polypeptide in First-Degree Relatives of Patients With Type 2 Diabetes. <i>Diabetes</i> , 2001, 50, 2497-2504.	0.3	206
255	Glucagon-Like Peptide 1 Increases Secretory Burst Mass of Pulsatile Insulin Secretion in Patients With Type 2 Diabetes and Impaired Glucose Tolerance. <i>Diabetes</i> , 2001, 50, 776-784.	0.3	62
256	Modified hyperinsulinaemic, eu- and hypoglycaemic clamp technique using lispro-insulin for insulinoma diagnostic. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2001, 109, 397-401.	0.6	2
257	Cloning and quantitative determination of the human Ca ²⁺ /calmodulin-dependent protein kinase II (CaMK II) isoforms in human beta cells. <i>Diabetologia</i> , 2000, 43, 465-473.	2.9	26
258	Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide). <i>European Heart Journal</i> , 2000, 21, 220-229.	1.0	69
259	Has a single blood glucose estimation on admission to hospital any prognostic value for acute pancreatitis?. <i>Gastroenterology</i> , 2000, 118, A1143.	0.6	0
260	DOES GLUCAGON STIMULATION PREDICT ORAL GLUCOSE TOLERANCE IN PATIENTS AFTER SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION?1. <i>Transplantation</i> , 2000, 70, 545-547.	0.5	3
261	Is glucagon-like peptide 1 an incretin hormone?. <i>Diabetologia</i> , 1999, 42, 373-379.	2.9	100
262	Six Methods for the Determination of C-Peptide Evaluated. <i>Clinical Chemistry and Laboratory Medicine</i> , 1999, 37, 745-51.	1.4	6
263	Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to α -glucosidase inhibition (acarbose) in Type 2 diabetic patients. , 1998, 15, 485-491.		119
264	Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in Type 2 diabetic patients. , 1998, 15, 937-945.		43
265	Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective. <i>Acta Diabetologica</i> , 1998, 35, 117-129.	1.2	75
266	Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1. <i>Peptides</i> , 1998, 19, 1049-1053.	1.2	69
267	Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1998, 106, 103-107.	0.6	21
268	Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. <i>Diabetes Care</i> , 1998, 21, 1925-1931.	4.3	116
269	Glucagon-Like Peptide 1 and its Potential in the Treatment of Non-Insulin-Dependent Diabetes Mellitus. <i>Hormone and Metabolic Research</i> , 1997, 29, 411-416.	0.7	53
270	Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for Type 2-diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1997, 105, 187-195.	0.6	133

#	ARTICLE	IF	CITATIONS
271	Absence of severe hyperinsulinemia after pancreas/kidney transplantation with peripheral venous drainage. <i>Transplantation Proceedings</i> , 1997, 29, 645-646.	0.3	15
272	Prediction of glucose tolerance with glucagon stimulation in pancreas transplanted patients. <i>Transplantation Proceedings</i> , 1997, 29, 3122-3123.	0.3	2
273	Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1997, 273, E981-E988.	1.8	423
274	A liquid mixed meal or exogenous glucagon-like peptide 1 (GLP-1) do not alter plasma leptin concentrations in healthy volunteers. <i>Acta Diabetologica</i> , 1997, 34, 230-234.	1.2	13
275	The pathogenesis of NIDDM involves a defective expression of the GIP receptor. <i>Diabetologia</i> , 1997, 40, 984-986.	2.9	104
276	Comparison of hyperinsulinaemic clamp experiments using venous, $\tilde{\text{arterialized}}$ venous or capillary euglycaemia. <i>Clinical Physiology</i> , 1996, 16, 589-602.	0.7	17
277	Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. <i>Diabetologia</i> , 1996, 39, 1546-1553.	2.9	286
278	Determinants of a normal (versus impaired) oral glucose tolerance after combined pancreas-kidney transplantation in IDDM patients. <i>Diabetologia</i> , 1996, 39, 462-468.	2.9	27
279	Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 327-332.	1.8	422
280	Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7-36) amide in type I diabetic patients. <i>Diabetes Care</i> , 1996, 19, 580-586.	4.3	310
281	On the Effects of Glucagon-Like Peptide-1 on Blood Glucose Regulation in Normal and Diabetic Subjects. <i>Annals of the New York Academy of Sciences</i> , 1996, 805, 729-736.	1.8	16
282	Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7?36 amide] in the fasting state in healthy subjects. <i>Acta Diabetologica</i> , 1995, 32, 13-16.	1.2	105
283	Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7?36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. <i>Diabetologia</i> , 1995, 38, 720-725.	2.9	212
284	Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-I but not by CCK-8. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1995, 268, E949-E955.	1.8	33
285	Glucagon-like Peptide 1 (7-36 hide) Secretion in Response to Luminal Sucrose from the Upper and Lower Gut: A Study Using $\hat{\pm}$ -Glucosidase Inhibition (Acarbose). <i>Scandinavian Journal of Gastroenterology</i> , 1995, 30, 892-896.	0.6	176
286	Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects. <i>Diabetes</i> , 1995, 44, 1126-1131.	0.3	721
287	Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7?36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. <i>Diabetologia</i> , 1995, 38, 720-725.	2.9	11
288	Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. <i>Diabetes</i> , 1995, 44, 1126-1131.	0.3	559

#	ARTICLE	IF	CITATIONS
289	Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation. <i>Acta Diabetologica</i> , 1993, 30, 39-45.	1.2	47
290	Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients. <i>Diabetologia</i> , 1993, 36, 741-744.	2.9	1,033
291	Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1993, 76, 912-917.	1.8	389
292	Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. <i>Journal of Clinical Investigation</i> , 1993, 91, 301-307.	3.9	1,401
293	Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1993, 76, 912-917.	1.8	318
294	Role of Endogenously Released Cholecystokinin in Determining Postprandial Insulin Levels in Man: Effects of Loxiglumide, a Specific Cholecystokinin Receptor Antagonist. <i>Digestion</i> , 1992, 53, 189-199.	1.2	20
295	Lack of Effect of Synthetic Human Gastric Inhibitory Polypeptide and Glucagon-Like Peptide 1 [7-36 Amide] Infused at Near-Physiological Concentrations on Pentagastrin-Stimulated Gastric Acid Secretion in Normal Human Subjects. <i>Digestion</i> , 1992, 52, 214-221.	1.2	49
296	Critical evaluation of the "heated hand" technique™ for obtaining "arterialized"™ venous blood: incomplete arterialization and alterations in glucagon responses. <i>Clinical Physiology</i> , 1992, 12, 537-552.	0.7	37
297	Basal and nutrient-stimulated pancreatic and gastrointestinal hormone concentrations in type-1-diabetic patients after successful combined pancreas and kidney transplantation. <i>The Clinical Investigator</i> , 1992, 70, 40-48.	0.6	7
298	Prolonged Maximal Stimulation of Insulin Secretion in Healthy Subjects Does Not Provoke Preferential Release of Proinsulin. <i>Pancreas</i> , 1991, 6, 645-652.	0.5	17
299	Insulinotropic Properties of Synthetic Human Gastric Inhibitory Polypeptide in Man: Interactions with Glucose, Phenylalanine, and Cholecystokinin-8. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1989, 69, 654-662.	1.8	105
300	Effects of single and combined infusions of human biosynthetic proinsulin and insulin on glucose metabolism and on plasma hormone concentrations in euglycaemic clamp experiments. <i>Hormone and Metabolic Research Supplement Series</i> , 1988, 18, 60-7.	0.2	1
301	Incretin Effects of Increasing Glucose Loads in Man Calculated from Venous Insulin and C-Peptide Responses*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1986, 63, 492-498.	1.8	752